Replies to post #2137 on Pozen Inc. (POZN)

[surf1944]

Pozen brings in digital advisers
Triangle Business Journal - by Dale Gibson
Date: Tuesday, July 19, 2011, 9:32am EDT

John Plachetka heads up Pozen.
Steve Wilson

John Plachetka heads up Pozen.

Digital and drugs are two words you don’t find together often. Chapel Hill pharma believes the two can fit like hand in glove to more effective move drugs forward to commercialization.

PozenbizWatch (Nasdaq:POZN) has established a digital advisory board, which the company describes as made up of “an esteemed group of digital thought-leaders both in and outside of healthcare to help progress the Company’s vision for revolutionizing the traditional pharmaceutical commercial model.”

The board will be called on to help Pozen and CEO John Plachetka use digital technology to “more effectively and efficiently engage and communicate with customers.”

http://www.bizjournals.com/triangle/news/2011/07/19/pozen-brings-in-digital-advisers.html?ana=yfcpc

[surf1944]

7:32AM POZEN misses by $0.02, misses on revs (POZN) 4.53 : Reports Q2 (Jun) loss of $0.21 per share, $0.02 worse than the Capital IQ Consensus Estimate of ($0.19); revenues fell 83.7% year/year to $4.6 mln vs the $5.4 mln consensus. During 2011, co plans to continue the late-stage clinical development of PA32540, along with its pre-commercialization activities. Additionally, co expects that patent litigation costs will be substantially less than the $9.4 mln spent in 2010. Given that the final verdict on the Treximet patent litigation has not been issued, and the VIMOVO launch is still in its early stages, the co pany will not provide annual financial guidance at this time. At June 30, 2011, cash, cash equivalents and short-term investments totaled $52.6 mln compared to $64.1 mln at December 31, 2010